Vecima Announces Creation of Office of the CTO and Executive Leadership Changes
20.7.2020 18:50:00 EEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) announced today that it has made several organizational changes across the executive leadership team in alignment with the company’s growth and operational objectives.
Mr. Clay McCreery has been appointed Chief Operating Officer. Mr. McCreery previously served as Chief Revenue Officer for Vecima, as well as managing operations for the Content Delivery & Storage business unit. He joined Vecima through the acquisition of Concurrent Technology in 2017. Prior to joining Concurrent, Mr. McCreery was Senior Vice President of Sales of North America at ARRIS for 14 years. During his tenure there, he helped integrate several key acquisitions enabling ARRIS’ market share growth in Access Technologies, DOCSIS Services, and Content Delivery. “This is a pivotal time for the company and the industries we serve. I am thrilled to be part of an organization with the vision and determination to help our customers transition their networks for next-generation services,” said Mr. McCreery.
Mr. Colin Howlett has been appointed Chief Technology Officer and will lead the newly created Office of the CTO. Mr. Howlett previously served as Vice President of Architecture at Vecima, and his tenure with the company spans 23 years, leading engineering and architecture teams. His technical expertise spans a wide breadth, including wireless, wireline, RF, and software engineering. “Throughout my previous roles at Vecima, the aspect I’ve enjoyed most is partnering with the customers we serve to develop unique and compelling solutions to their technical challenges,” said Mr. Howlett. “I look forward to leading a team of world-class technology experts and industry thought leaders as we expand our reach.”
Mr. Kyle Goodwin has been promoted to SVP & General Manager of the Content Delivery & Storage business unit. Mr. Goodwin previously led Concurrent Technology’s research and development portfolio of products through a time of transition in the service provider industry. Prior to joining Concurrent, he spent time in the telecommunications, financial technology, and insurance industries with Motorola, PrimeRevenue, S1 Corporation, and Aflac. Mr. Goodwin is also a Steering Board Member of the DVB Project, an industry-led consortium defining the global standard for digital television.
Mr. Ryan Nicometo has been promoted to SVP & General Manager of the Video & Broadband Solutions business unit. Mr. Nicometo, who also joined Vecima from the acquisition of Concurrent Technology, brings 21 years of experience in the service provider space to his role. Prior to joining Concurrent, he held leadership roles at ARRIS Group, CCI Systems, and Motorola. While at Motorola and ARRIS, he helped integrate technology and talent from several acquisitions across roles in sales and product management.
Mr. Goodwin and Mr. Nicometo will report to Mr. McCreery in their new roles with the company.
“Both Ryan and Kyle have been key members of the management team and have been significant contributors in the success of the company over the last several years,” said Mr. McCreery.
“I am very excited to have Clay, Colin, Kyle, and Ryan take on expanded roles within the Vecima leadership team as we continue to execute on our strategy to serve our global service provider and broadcast customers with a powerful suite of products and technologies that fuel a more connected world,” said Mr. Sumit Kumar, President and Chief Executive Officer of Vecima. “Vecima is positioned for growth and investing in the futures of the industries we serve.”
About Vecima
Vecima Networks Inc. is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high-capacity broadband network access, and streamline data analytics. For more information, please visit our website at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005209/en/
Contact information
Vecima Networks
Investor Relations – 250-881-1982
invest@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release
Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 14:00:00 EEST | Press release
Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and self-adhesive product solutions. Operating across six global regions and serving both complex industrial and fast-moving consumer markets, t
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 14:00:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom